203 related articles for article (PubMed ID: 24687970)
1. HER2 and GATA4 are new prognostic factors for early-stage ovarian granulosa cell tumor-a long-term follow-up study.
Färkkilä A; Andersson N; Bützow R; Leminen A; Heikinheimo M; Anttonen M; Unkila-Kallio L
Cancer Med; 2014 Jun; 3(3):526-36. PubMed ID: 24687970
[TBL] [Abstract][Full Text] [Related]
2. FOXL2, GATA4, and SMAD3 co-operatively modulate gene expression, cell viability and apoptosis in ovarian granulosa cell tumor cells.
Anttonen M; Pihlajoki M; Andersson N; Georges A; L'hôte D; Vattulainen S; Färkkilä A; Unkila-Kallio L; Veitia RA; Heikinheimo M
PLoS One; 2014; 9(1):e85545. PubMed ID: 24416423
[TBL] [Abstract][Full Text] [Related]
3. Granulosa Cell Tumors: Novel Predictors of Recurrence in Early-stage Patients.
Sakr S; Abdulfatah E; Thomas S; Al-Wahab Z; Beydoun R; Morris R; Ali-Fehmi R; Bandyopadhyay S
Int J Gynecol Pathol; 2017 May; 36(3):240-252. PubMed ID: 28727617
[TBL] [Abstract][Full Text] [Related]
4. GATA4 protects granulosa cell tumors from TRAIL-induced apoptosis.
Kyrönlahti A; Kauppinen M; Lind E; Unkila-Kallio L; Butzow R; Klefström J; Wilson DB; Anttonen M; Heikinheimo M
Endocr Relat Cancer; 2010 Sep; 17(3):709-17. PubMed ID: 20554787
[TBL] [Abstract][Full Text] [Related]
5. Transformation in recurrent ovarian granulosa cell tumors: Ki67 (MIB-1) and p53 immunohistochemistry demonstrates a possible molecular basis for the poor histopathologic prediction of clinical behavior.
Costa MJ; Walls J; Ames P; Roth LM
Hum Pathol; 1996 Mar; 27(3):274-81. PubMed ID: 8600043
[TBL] [Abstract][Full Text] [Related]
6. High GATA-4 expression associates with aggressive behavior, whereas low anti-Müllerian hormone expression associates with growth potential of ovarian granulosa cell tumors.
Anttonen M; Unkila-Kallio L; Leminen A; Butzow R; Heikinheimo M
J Clin Endocrinol Metab; 2005 Dec; 90(12):6529-35. PubMed ID: 16159935
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA profiling of ovarian granulosa cell tumours reveals novel diagnostic and prognostic markers.
Cheng WT; Rosario R; Muthukaruppan A; Wilson MK; Payne K; Fong PC; Shelling AN; Blenkiron C
Clin Epigenetics; 2017; 9():72. PubMed ID: 28736583
[TBL] [Abstract][Full Text] [Related]
8. GATA4 immunolocalization in breast carcinoma as a potent prognostic predictor.
Takagi K; Moriguchi T; Miki Y; Nakamura Y; Watanabe M; Ishida T; Yamamoto M; Sasano H; Suzuki T
Cancer Sci; 2014 May; 105(5):600-7. PubMed ID: 24862985
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors.
Färkkilä A; Anttonen M; Pociuviene J; Leminen A; Butzow R; Heikinheimo M; Unkila-Kallio L
Eur J Endocrinol; 2011 Jan; 164(1):115-22. PubMed ID: 21041381
[TBL] [Abstract][Full Text] [Related]
10. HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort.
Rouanet P; Roger P; Rousseau E; Thibault S; Romieu G; Mathieu A; Cretin J; Barneon G; Granier M; Maran-Gonzalez A; Daures JP; Boissiere F; Bibeau F
Cancer Med; 2014 Feb; 3(1):134-42. PubMed ID: 24407937
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and survival of patients with an adult-type ovarian granulosa cell tumor: a 56-year single-center experience.
Bryk S; Färkkilä A; Bützow R; Leminen A; Heikinheimo M; Anttonen M; Riska A; Unkila-Kallio L
Int J Gynecol Cancer; 2015 Jan; 25(1):33-41. PubMed ID: 25347095
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors of ovarian granulosa cell tumor: a study of 35 patients and review of the literature.
Auranen A; Sundström J; Ijäs J; Grénman S
Int J Gynecol Cancer; 2007; 17(5):1011-8. PubMed ID: 17374124
[TBL] [Abstract][Full Text] [Related]
14. Outcome of patients with recurrent adult-type granulosa cell tumors--a Taiwanese Gynecologic Oncology Group study.
Wang PH; Sun HD; Lin H; Wang KL; Liou WS; Hung YC; Chiang YC; Lu CH; Lai HC; Chang TC;
Taiwan J Obstet Gynecol; 2015 Jun; 54(3):253-9. PubMed ID: 26166336
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
[TBL] [Abstract][Full Text] [Related]
16. FOXO1/3 and PTEN Depletion in Granulosa Cells Promotes Ovarian Granulosa Cell Tumor Development.
Liu Z; Ren YA; Pangas SA; Adams J; Zhou W; Castrillon DH; Wilhelm D; Richards JS
Mol Endocrinol; 2015 Jul; 29(7):1006-24. PubMed ID: 26061565
[TBL] [Abstract][Full Text] [Related]
17. GATA-4 regulates Bcl-2 expression in ovarian granulosa cell tumors.
Kyrönlahti A; Rämö M; Tamminen M; Unkila-Kallio L; Butzow R; Leminen A; Nemer M; Rahman N; Huhtaniemi I; Heikinheimo M; Anttonen M
Endocrinology; 2008 Nov; 149(11):5635-42. PubMed ID: 18653721
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with an increased risk of recurrence in women with ovarian granulosa cell tumors.
Suri A; Carter EB; Horowitz N; Denslow S; Gehrig PA
Gynecol Oncol; 2013 Nov; 131(2):321-4. PubMed ID: 23994106
[TBL] [Abstract][Full Text] [Related]
19. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
[TBL] [Abstract][Full Text] [Related]
20. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G
Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
